Qiagen Discloses It Spent up to $181.7M on Recent Acquisitions

May 09, 2012

|

NEW YORK (GenomeWeb News) – Qiagen made three acquisitions in April and May for up to $181.7 million, it disclosed in a document filed yesterday with the US Securities and Exchange Commission.

In its Form 10-Q Qiagen said that the acquisitions included the remaining 60 percent of Scandinavian Gene Synthesis that it didn't already own, and AmniSure International. Qiagen did not provide details on its third acquisition.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

When the Ailment You're Studying Becomes Personal

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

Irish Genomics Initiative Looks to Expand Into Scotland

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

Another Source of Data for 23andMe

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

This Week in PLOS

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.

Main menu